Warning: The NCBI web site requires JavaScript to function. more...
TRIPS, the Doha declaration and paragraph 6 decision: what are the remaining steps for protecting access to medicines?
Kerry VB, Lee K.
Global Health. 2007 May 24;3:3.
Related citations
TRIPS, the Doha Declaration and increasing access to medicines: policy options for Ghana.
Cohen JC, Gyansa-Lutterodt M, Torpey K, Esmail LC, Kurokawa G.
Global Health. 2005 Dec 9;1:17.
Addressing legal and political barriers to global pharmaceutical access: options for remedying the impact of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) and the imposition of TRIPS-plus standards.
Cohen-Kohler JC, Forman L, Lipkus N.
Health Econ Policy Law. 2008 Jul;3(Pt 3):229-56.
Managing the effect of TRIPS on availability of priority vaccines.
Milstien J, Kaddar M.
Bull World Health Organ. 2006 May;84(5):360-5. Epub 2006 May 17.
[Evolution of the international intellectual property rights system: patent protection for the pharmaceutical industry and access to medicines].
Chaves GC, Oliveira MA, Hasenclever L, de Melo LM.
Cad Saude Publica. 2007 Feb;23(2):257-67. Review. Portuguese.
WTO ministerial conference adopts declaration on TRIPS and public health.
Elliott R.
Can HIV AIDS Policy Law Rev. 2002 Mar;6(3):50-2.
Trade, TRIPS, and pharmaceuticals.
Smith RD, Correa C, Oh C.
Lancet. 2009 Feb 21;373(9664):684-91. Epub 2009 Jan 21.
Poverty, health & intellectual property rights with special reference to India.
Satyanarayana K, Srivastava S.
Indian J Med Res. 2007 Oct;126(4):390-406.
Has the implementation of the TRIPS Agreement in Latin America and the Caribbean produced intellectual property legislation that favours public health?
Oliveira MA, Bermudez JA, Chaves GC, Velásquez G.
Bull World Health Organ. 2004 Nov;82(11):815-21. Epub 2004 Dec 14.
Driving a decade of change: HIV/AIDS, patents and access to medicines for all.
Hoen E, Berger J, Calmy A, Moon S.
J Int AIDS Soc. 2011 Mar 27;14:15. Review.
The UNESCO Bioethics Declaration 'social responsibility' principle and cost-effectiveness price evaluations for essential medicines.
Faunce TA.
Monash Bioeth Rev. 2005 Jul;24(3):10-9.
Canada's implementation of the Paragraph 6 Decision: is it sustainable public policy?
Cohen-Kohler JC, Esmail LC, Cosio AP.
Global Health. 2007 Dec 6;3:12.
Implications of bilateral free trade agreements on access to medicines.
Correa CM.
Bull World Health Organ. 2006 May;84(5):399-404. Epub 2006 May 17.
TRIPS and the global pharmaceutical market.
Barton JH.
Health Aff (Millwood). 2004 May-Jun;23(3):146-54.
A proposal for measuring the degree of public health-sensitivity of patent legislation in the context of the WTO TRIPS Agreement.
Chaves GC, Oliveira MA.
Bull World Health Organ. 2007 Jan;85(1):49-56.
Scrutinized: the TRIPS agreement and public health.
Subhan J.
Mcgill J Med. 2006 Jul;9(2):152-9.
Oslo Ministerial Declaration--global health: a pressing foreign policy issue of our time.
[No authors listed]
Lancet. 2007 Apr 21;369(9570):1373-8.
Access to generic antiretrovirals: inequality, intellectual property law, and international trade agreements.
Castro A, Westerhaus M.
Cad Saude Publica. 2007;23 Suppl 1:S85-96.
International trade agreements: a threat to tobacco control policy.
Shaffer ER, Brenner JE, Houston TP.
Tob Control. 2005 Aug;14 Suppl 2:ii19-25. Review.
Affordable antiretroviral drugs for the under-served markets: how to expand equitable access against the backdrop of challenging scenarios?
Dionisio D, Cao Y, Hongzhou L, Kraisintu K, Messeri D.
Curr HIV Res. 2006 Jan;4(1):3-20. Review.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on